A valid CJC-1295 No DAC test report provides quantitative, third-party analytical verification confirming peptide purity, correct sequence mass, and safety from microbial contaminants. When evaluating a Certificate of Analysis for this growth-hormone-releasing hormone analog, laboratory researchers must verify Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) purity values above 98%, Mass Spectrometry (ESI-MS) molecular mass matching the 3,367.9 Da theoretical standard, and endotoxin levels beneath strict research thresholds.
A valid CJC-1295 No DAC test report provides quantitative, third-party analytical verification confirming peptide purity, correct sequence mass, and safety from microbial contaminants. When evaluating a Certificate of Analysis for this growth-hormone-releasing hormone analog, laboratory researchers must verify Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) purity values above 98%, Mass Spectrometry (ESI-MS) molecular mass matching the 3,367.9 Da theoretical standard, and endotoxin levels beneath strict research thresholds.
In contemporary bio-analytical evaluation, obtaining a verified cjc-1295 no dac test report is essential for confirming that experimental reagents meet exact specifications. CJC-1295 No DAC (also known as Modified GRF 1-29) is a synthetic 29-amino-acid peptide derivative of growth-hormone-releasing hormone (GHRH). Preclinical research indicates that this GHRH analog binds selectively to the GHRH receptor, stimulating the pulsatile release of endogenous growth hormone (GH) and downstream insulin-like growth factor 1 (IGF-1) to evaluate signaling pathways involved in cellular regeneration and tissue repair.
Because synthetic peptide manufacturing via Solid-Phase Peptide Synthesis (SPPS) can produce deletion sequences, truncated fragments, and racemized side products, analytical validation cannot rely solely on supplier declarations. A comprehensive test report must originate from an independent, ISO 17025-accredited laboratory utilizing standardized chromatographic and spectroscopic instrumentation. Primary metrics documented in a rigorous assay include chromatic purity percentage, electrospray ionization mass spec (ESI-MS) target confirmation, counter-ion TFA salt residue, residual solvent limits, and bacterial endotoxin load quantified via Limulus Amebocyte Lysate (LAL) testing.
Researchers analyzing a cjc-1295 no dac test report must cross-reference lot numbers between the vial label and the analytical document. A legitimate supplier publishes lot-specific documentation for every production batch rather than relying on historical templates. Comprehensive documentation ensures reproducible empirical results across repeated in vitro and animal study models.
Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC) is the gold-standard analytical separation method used to determine the chemical purity of synthetic peptides. In an RP-HPLC test report, the sample is dissolved in an aqueous mobile phase and injected onto a hydrophobic stationary phase column (typically C18). Peptides and related impurities elute based on differential hydrophobic interactions, yielding a chromatogram measured at a specific UV absorbance wavelength (typically 214 nm or 220 nm for peptide backbone detection).
When auditing an RP-HPLC chromatogram within a cjc-1295 no dac test report, investigators should review the primary peak area relative to total integrated peak areas. The principal peak representing pure CJC-1295 No DAC must exhibit sharp, symmetrical morphology without shoulder peaks, fronting, or tailing, which indicate co-eluting isomeric impurities or degradation products. Reliable research grade material yields a purity integration of no less than 98.0%, with minor synthesis-related impurities individually accounting for less than 0.5% of total integration.
A common point of vulnerability in unverified reports is baseline manipulation. Low-tier analytical testing may artificially crop chromatograms, alter integration thresholds, or adjust baseline parameters to mask deletion peptides. Legitimate reports display the full run duration (typically 30 to 60 minutes), complete gradient conditions, mobile phase composition (e.g., water/acetonitrile with 0.1% trifluoroacetic acid), and full baseline integration from the injection peak to column wash phases. Researchers can consult our peptide purity testing guide to better understand chromatic integration parameters.
While RP-HPLC establishes chromatographic purity, it cannot confirm structural identity. Two distinct peptides with similar hydrophobic properties may elute at identical retention times. Therefore, an authentic cjc-1295 no dac test report must include Mass Spectrometry analysis, typically executed via Electrospray Ionization Mass Spectrometry (ESI-MS) or Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF).
The theoretical molecular weight of CJC-1295 No DAC (Modified GRF 1-29, sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2) is precisely 3,367.9 Da (g/mol). In ESI-MS reports, the instrument measures the mass-to-charge ratio (m/z) of multi-charged species generated during ionization. Common charge states observed for this peptide include [M+3H]3+ at approximately m/z 1123.6, [M+4H]4+ at m/z 843.0, and [M+5H]5+ at m/z 674.6.
Deconvolution of these observed charge-state peaks must yield a calculated monoisotopic or average molecular weight within ±1.0 Da of the theoretical 3,367.9 Da target. The presence of secondary mass peaks matching standard deletion sequences (such as -Ala or -Ser fragments) or incomplete deprotection steps indicates compromised synthesis control. Verification of precise mass data ensures that GHRH analogs match their target primary sequence prior to deployment in cell culture assays.
Endotoxins, specifically lipopolysaccharides (LPS) derived from the outer membrane of Gram-negative bacteria, represent a major confounding variable in biological research. Even highly purified synthetic peptides can harbor pyrogenic endotoxin contamination introduced during synthesis reagents, purification buffers, or lyophilization processes. In cellular assays and animal studies, trace endotoxins stimulate Toll-like receptor 4 (TLR4), triggering systemic inflammatory cascades, cytokine release, and cell toxicity that distort experimental outcomes.
A rigorous cjc-1295 no dac test report includes quantitative endotoxin evaluation performed via the Limulus Amebocyte Lysate (LAL) assay or recombinant Factor C (rFC) methodology. For high-grade research reagents, endotoxin levels are reported in Endotoxin Units per milligram (EU/mg). Standard analytical grade specifications require endotoxin concentrations to be less than 1.0 EU/mg, with premium research grade compounds achieving levels under 0.1 EU/mg.
Excluding endotoxin verification from lab protocols risks invalidating downstream research data. When evaluating signaling pathways mediated by GHRH receptors, unwanted TLR4 activation caused by endotoxin impurities alters gene expression profiles and cell viability markers. Independent LAL testing ensures that observed bioactivity is attributable solely to the target peptide structure.
Distinguishing genuine third-party analytical documentation from fabricated or misleading testing reports requires a systematic audit of specific report components. As demand for specialized laboratory compounds expands, vendors may present altered certificates or partial testing metrics. The following table highlights critical red flags to identify during COA evaluation:
**Key Certificate of Analysis (COA) Audit Criteria:** - **Missing ESI-MS Data:** Presenting RP-HPLC purity without mass spectrometry leaves sequence identity unverified. - **Cropped Chromatogram Baselines:** Chromatograms that omit the baseline before or after the main peak often hide late-eluting impurities or synthesis degradation products. - **Inconsistent Batch Numbers:** Mismatches between the lot number listed on the test report and the lyophilized vial label indicate non-traceable inventory control. - **Absence of Endotoxin Metrics:** Omitting LAL assay results leaves cell cultures vulnerable to lipopolysaccharide-induced inflammatory responses. - **Generic Vendor-Generated PDF:** Self-issued certificates without third-party laboratory identification, signatures, analyst names, or ISO 17025 accreditation credentials. - **Unspecified Wavelength Integration:** HPLC runs conducted at non-standard UV wavelengths (e.g., 280 nm for non-aromatic sequences) to artificially suppress impurity peak areas.
To mitigate these vulnerabilities, institutional researchers must source material backed by batch-specific, verifiable documentation. At PX1 Research, every production lot of CJC-1295 No DAC undergoes independent analysis at accredited domestic laboratories, providing raw HPLC integration files and ESI-MS spectral data accessible through our PX1 research library.
Understanding the chemical structural distinctions across GHRH secretagogues is vital when reviewing analytical reports and designing comparative study protocols. CJC-1295 No DAC (Modified GRF 1-29) consists of the modified 29-amino-acid sequence without additional conjugation domains. In contrast, CJC-1295 with DAC incorporates a Lysine linker attached to a Drug Affinity Complex (DAC) maleimido propionyl group, raising the theoretical mass to 3,647.2 Da and allowing covalent binding to circulating albumin in animal models.
In analytical test reports, these structural variations manifest in distinct retention times and mass spectrometry profiles. While CJC-1295 No DAC exhibits rapid receptor binding kinetics and a shorter half-life in vitro, CJC-1295 DAC exhibits prolonged clearance curves due to its albumin-conjugating domain. Other related compounds in this secretagogue class include Sermorelin, which retains the native un-modified GHRH 1-29 sequence (3,357.9 Da), and Ipamorelin, a selective pentapeptide GH secretagogue acting via the ghrelin/GHS-R1a receptor pathway.
Comparative analytical evaluation reveals how subtle amino acid substitutions influence chemical stability and chromatographic retention. For instance, the substitution of D-Ala at position 2 in CJC-1295 No DAC protects the peptide backbone from rapid cleavage by dipeptidyl peptidase-4 (DPP-IV), a degradation event that can be monitored quantitatively via stability-indicating RP-HPLC assays over time. Related secretagogues such as GHRP-2 or GHRP-6 are frequently analyzed alongside GHRH analogs in dual-pathway receptor binding assays.
During Solid-Phase Peptide Synthesis (SPPS), trifluoroacetic acid (TFA) is routinely employed for cleavage of the peptide chain from the resin support and for side-chain deprotection. Consequently, crude synthetic peptides are isolated as TFA salts. Excess residual TFA can alter solution pH upon reconstitution, potentially affecting sensitive cell culture models or accelerating peptide hydrolysis.
A complete cjc-1295 no dac test report includes determination of residual TFA content via ion chromatography (IC) or RP-HPLC with specialized mobile phases. Standard peptide lyophilizates generally contain 10% to 15% TFA by weight unless post-synthesis salt exchange to acetate or hydrochloride forms is performed. Documenting TFA content allows researchers to accurately calculate net peptide content (actual peptide mass versus total powder mass).
Additionally, moisture content measured via Karl Fischer titration or Loss on Drying (LOD) should be documented. Residual water content in lyophilized cakes should remain below 5.0% to prevent non-enzymatic hydrolysis during long-term storage. High-purity compounds supplied for institutional study, available through our wholesale laboratory accounts, strictly quantify net peptide content and moisture parameters to guarantee exact molar dosing in analytical preparation.
To maintain the analytical purity confirmed in a cjc-1295 no dac test report, proper handling, storage, and reconstitution procedures must be strictly enforced within the laboratory setting. Lyophilized peptide cakes are stable when stored at -20°C to -80°C in a desiccated environment protected from light.
Reconstitution protocols for in vitro experimentation must use sterile, endotoxin-free solvents. Bacteriostatic Water (0.9% benzyl alcohol) or sterile 0.9% Sodium Chloride solution is commonly used depending on cell culture tolerance. When reconstituting, the diluent should be introduced down the inner glass wall of the vial to minimize mechanical agitation. Gentle swirling should be applied; vigorous shaking must be avoided to prevent peptide aggregation and air-interface denaturation.
Once reconstituted, aqueous solutions of CJC-1295 No DAC demonstrate limited stability at room temperature. Solutions should be stored at 2°C to 8°C and utilized within 14 to 28 days depending on solvent antimicrobial preservation. For extended experimental timelines, reconstituted aliquots should be flash-frozen in liquid nitrogen and maintained at -80°C to minimize freeze-thaw degradation cycles. Repeated freeze-thaw cycles alter primary structure stability and induce aggregation detectable via analytical SEC-HPLC.
Selecting a reliable supplier for research-grade peptides requires evaluating manufacturing consistency, analytical transparency, and domestic logistics. PX1 Research synthesizes compounds in state-of-the-art facilities utilizing modern automated SPPS equipment, followed by dual-stage purification using preparative HPLC.
Every batch of CJC-1295 No DAC undergoes comprehensive testing by independent ISO 17025 certified laboratories within the USA. Each shipment is accompanied by a full lot-specific Certificate of Analysis detailing RP-HPLC chromatograms, ESI-MS mass spec readouts, LAL endotoxin levels, and net peptide content. Products ship directly from our California and Arizona fulfillment centers, with same-day shipping available Monday through Friday for orders placed prior to cut-off times.
Whether executing small-scale assays or managing large academic research initiatives, securing standardized compounds ensures experimental reproducibility. Institutional buyers seeking verified purity parameters can browse our full catalog of all peptides or contact our technical support team to set up streamlined procurement channels.
cjc-1295 no dac test report
A valid CJC-1295 No DAC test report is an independent Certificate of Analysis (COA) that verifies the chemical purity (typically >98% by RP-HPLC), exact molecular weight (3,367.9 Da by ESI-MS), and endotoxin concentration (<1.0 EU/mg by LAL assay) for a specific production lot.
What should I look for in a valid CJC-1295 no dac test report?
Look for third-party accreditation (ISO 17025 lab), an uncropped RP-HPLC chromatogram showing >98% purity, an ESI-MS spectrum confirming target mass (3,367.9 Da), LAL endotoxin testing results (<1.0 EU/mg), matching lot numbers on the vial and report, and clear contact information for the testing laboratory.
How is purity quantified on a CJC-1295 No DAC HPLC chromatogram?
Purity is quantified by calculating the area under the curve (AUC) of the primary peak relative to the total area of all integrated peaks detected at 214 nm or 220 nm UV absorbance during reverse-phase chromatography.
What is the expected molecular weight on a CJC-1295 No DAC mass spectrometry report?
The theoretical molecular weight of CJC-1295 No DAC (Modified GRF 1-29) is 3,367.9 Da. The mass spectrometry report should show deconvoluted peaks matching this mass within a ±1.0 Da tolerance.
Why is endotoxin testing critical for CJC-1295 No DAC research compounds?
Endotoxins (lipopolysaccharides) trigger inflammatory responses via TLR4 activation in cell cultures and animal models. Endotoxin testing via LAL assay ensures that experimental results reflect peptide activity rather than microbial contamination.
What are the main quality red flags on a supplier's peptide Certificate of Analysis?
Key red flags include missing mass spectrometry data, cropped HPLC baseline integrations, absence of endotoxin metrics, mismatched lot numbers between report and product, generic vendor-issued certificates without independent lab details, and abnormal retention time shifts.
How does CJC-1295 No DAC differ structurally and analytically from CJC-1295 with DAC?
CJC-1295 No DAC is a 29-amino-acid GHRH analog with a molecular weight of 3,367.9 Da. CJC-1295 with DAC includes a maleimido propionyl Lysine linker that increases its weight to 3,647.2 Da, allowing covalent binding to serum albumin in vivo.
How should CJC-1295 No DAC be reconstituted for in vitro analytical research?
Reconstitute using sterile bacteriostatic water or sterile 0.9% saline. Direct the diluent down the glass wall of the vial, allow the powder to dissolve, and gently swirl without shaking to avoid mechanical agitation and foaming.
What temperature settings are required for long-term storage of CJC-1295 No DAC lyophilizate?
Lyophilized CJC-1295 No DAC should be stored desiccated at -20°C for short to medium terms or at -80°C for long-term storage to prevent moisture absorption and peptide degradation.
How can research institutions secure lot-specific COAs for bulk peptide orders?
Institutional researchers can request lot-specific analytical reports through specialized supplier portals or set up verified procurement pathways via PX1 Research wholesale laboratory accounts.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.